Gonadotrophins in ovulation induction

Reproductive BioMedicine Online

Volumn 10, Issue SUPPL. 3, 2005, Pages 25-31

  Macklon, Nick S ^a   Fauser, B C J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anovulation; FSH; Gonadotrophins; Monofollicular; Step down; Step up

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; DEXAMETHASONE; FOLLITROPIN; GLUCOCORTICOID; GONADORELIN AGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; METFORMIN; PLACEBO; PREDNISONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ANOVULATION; ARTICLE; BODY WEIGHT DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONCEPTION; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; FERTILIZATION IN VITRO; GLUCOSE INTOLERANCE; HUMAN; META ANALYSIS; MULTIPLE PREGNANCY; OVARY CYCLE; OVARY DISEASE; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATIENT MONITORING; PREDICTION; PROGNOSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 22244463572     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(11)60387-8     Document Type: Article

References (64)

1. Azziz R 1997 Glucocorticoid suppression in the treatment of androgen excess. In: Azziz R, Nestler JE, Dewailly D (eds) Androgen Excess Disorders in Women. Lippencott Williams & Wilkins, Philadelphia, USA, pp. 737-747.
2. Azziz R, Black VY, Knochenhauer ES et al. 1999 Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. Journal of Clinical Endocrinology and Metabolism 84, 946-950.
3. Baird DT 1987 A model for follicular selection and ovulation: lessons from superovulation. Journal of Steroid Biochemistry 27, 15-23.
4. Balasch J, Fabregues F, Creus M et al. 2000 Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol. Journal of Assisted Reproduction and Genetics 17, 561-565.
5. Balen A 2002 Is there a risk of prion disease after the administration of urinary-derived gonadotropins? Human Reproduction 17, 1676-1680.
6. Bayram N, van Wely M, van der Veen F 2001 Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews CD002121.
7. Bayram N, van Wely M, Kaaijk EM et al. 2004 Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. British Medical Journal 328, 192-197.
8. Bider D, Blankstein J, Levron J, Tur-Kaspa I 1997 Gonadotropins and glucocorticoid therapy for 'low responders' - a controlled study. Journal of Assisted Reproduction and Genetics 14, 328-331.
9. Brown JB 1978 Pituitary control of ovarian function - concepts derived from gonadotrophin therapy. Australian and New Zealand Journal of Obstetrics and Gynaecology 18, 47-54.
10. Buyalos RP, Geffner ME, Azziz R, Judd HL 1997 Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome. Human Reproduction 12, 1138-1141.
11. CDC Reproductive Health 2003 Section 6: ART trends, 1996-2000. wwwcdcgov.
12. Christin-Maitre S, Hugues JN 2003 A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Human Reproduction 18, 1626-1631.
13. Coelingh Bennink HJ, Fauser BC, Out HJ 1998 Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertility and Sterility 69, 19-25.
14. Collins JA, Hughes EG 1995 Pharmacological interventions for the induction of ovulation. Drugs 50, 480-494.
15. Devroey P, Fauser BC, Platteau P et al. 2004 Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 89, 2062-2070.
16. Dubourdieu S, Le Nestour E, Spitz IM et al. 1993 The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. Human Reproduction 8, 2056-2060.
17. Eijkemans MJ, Imani B, Mulders AG et al. 2003 High ongoing singleton live birth rate following classical ovulation induction in anovulatory infertility. Human Reproduction 18, 2357-2362.
18. European Recombinant Human Chorionic Gonadotrophin Study Group 2000 Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment-recombinant hCG versus urinary hCG. Human Reproduction 15, 1446-1451.
19. European Recombinant Human LH Study Group 2001 Human recombinant luteinizing hormon is as effective as, but safer than, urinary human chorionic gonadotrophin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. Journal of Clinical Endocrinology and Metabolism 86, 2607-2618.
20. Fauser BC 1998 Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Human Reproduction 13 (suppl. 3), 36-46.
21. Fauser BCJM, Macklon NS 2004 Medical Approaches to Ovarian Stimulation for Infertility. In: Strauss III J, Barbieri R (eds) Yen and Jaffe's Reproductive Endocrinology. Elsevier Science, Philadelphia.
22. Fauser BC, van Heusden AM 1997 Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocrine Reviews 18, 71-106.
23. Fauser BC, Donderwinkel P, Schoot DC 1993 The step-down principle in gonadotrophin treatment and the role of GnRH analogues. Bailliere's Clinical Obstetrics and Gynaecology 7, 309-330.
24. Fauser BCJM, Devroey P, Macklon NS 2005 Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 365, 1807-1816.
25. Filicori M, Cognigni GE, Samara A et al. 2002 The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Human Reproduction Update 8, 543-557.
26. Fleming R, Adam AH, Barlow DH et al. 1982 A new systematic treatment for infertile women with abnormal hormone profiles. British Journal of Obstetrics and Gynaecology 89, 80-83.
27. Franks S, Mason HD, Polson DW et al. 1988 Mechanism and management of ovulatory failure in women with polycystic ovary syndrome. Human Reproduction 3, 531-534.
28. Hall JE, Schoenfeld DA, Martin KA, Crowley WFJ 1992 Hypothalamic gonadotropin-releasing hormone secretion and follicle-stimulating hormone dynamics during the luteal-follicular transition. Journal of Clinical Endocrinology and Metabolism 74, 600-607.
29. Hayden CJ, Rutherford AJ, Balen AH 1999 Induction of ovulation with the use of a starting dose of 50 units of recombinant human follicle-stimulating hormone (Puregon). Fertility and Sterility 71, 106-108.
30. Hedon B, Hugues JN, Emperaire JC et al. 1998 A comparative study using r-hFSH in a low dose vs conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Human Reproduction 13, 2688-2692.
31. Hillier SG 1994 Current concepts of the role of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Human Reproduction 9, 188-191.
32. Hoffman D, Lobo RA 1985 Serum dehydroepiandrosterone sulfate and the use of clomiphene citrate in anovulatory women. Fertility Sterility 43, 196-199.
33. Hohmann FP, Laven JS, de Jong FH et al. 2001 Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development. Human Reproduction 16, 846-854.
34. Homburg R, Howles CM 1998 Low dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Human Reproduction Update 5, 493-499.
35. Hughes E, Collins J, Vandekerckhove P 2000 Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome. Cochrane Database of Systematic Reviews CD000097.
36. Hugues JN, Cédrin-Durnerin I, Avril C et al. 1996 Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome. Human Reproduction 11, 2581-2584.
37. Hugues JN, Bstandig B, Bry-Gauillard H et al. 2001 Comparison of the effectiveness of recombinant and urinary FSH preparations in the achievement of follicular selection in chronic anovulation. Reproductive BioMedicine Online 3, 195-198.
38. Hugues JN, Soussis J, Calderon I et al. 2005 Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose finding study. Human Reproduction 20, 629-635.
39. Imani B, Eijkemans MJ, Faessen GH et al. 2002 Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertility and Sterility 77, 83-90.
40. Le Nestour E, Marraoui J, Lahlou N et al. 1993 Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition. Journal of Clinical Endocrinology and Metabolism 77, 439-442.
41. Lopez E, Gunby J, Daya S et al. 2004 Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reproductive BioMedicine Online 9, 382-390.
42. Loumaye E, Engrand P, Shoham Z et al. 2003 Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Human Reproduction 18, 314-322.
43. Lunenfeld B 2004 Historical perspectives in gonadotrophin therapy. Human Reproduction Update 10, 453-467.
44. Mizunuma H, Takagi T, Yamada K et al. 1991 Ovulation induction by step-down administration of purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome. Fertility and Sterility 55, 1195-1196.
45. Mulders AG, Imani B, Eijkemans MJ, Fauser BC 2003a Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reproductive BioMedicine Online 7, 48-56.
46. Mulders AG, Laven JS, Eijkemans MJ et al. 2003b Patient predictors for outcome of gonadotropin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta analysis. Human Reproduction Update 9, 429-449.
47. Nugent D, Vandekerckhove P, Hughes E et al. 2000 Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews CD000410.
48. Polson DW, Mason HD, Kiddy DS et al. 1989 Low-dose follicle-stimulating hormone in the treatment of polycystic ovary syndrome: a comparison of pulsatile subcutaneous with daily intramuscular therapy. British Journal of Obstetric and Gynaecology 96, 746-748.
49. Schipper I, Hop WC, Fauser BC 1998 The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. Journal of Clinical Endocrinology and Metabolism 83, 1292-1298.
50. Schoot DC, Pijlman B, Stijnen T, Fauser BC 1992 Effects of gonadotropin releasing hormone agonist addition to gonadotropin induction of ovulation in polycystic ovary syndrome patients. European Journal of Obstetrics Gynecology and Reproductive Biology 45, 53-58.
51. Schoot DC, Hop WC, Pache TD et al. 1993 Growth of the dominant follicle is similar to normal in patients with gonadotrophin-stimulated polycystic ovary syndrome exhibiting monofollicular development during a decremental dose regimen. Acta Endocrinologica (Copenhagen) 129, 126-129.
52. Schoot DC, Hop WC, de Jong FH et al. 1995 Initial estradiol response predicts outcome of exogenous gonadotropins using a step-down dose regimen for induction of ovulation in polycystic ovary syndrome. Fertility and Sterility 64, 1081-1087.
53. Shoham Z 2002 The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertility and Sterility 77, 1170-1177.
54. Shoham Z, Jacobs HS, Insler V 1993 Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertility and Sterility 59, 1153-1161.
55. Sullivan MW, Stewart-Akers A, Krasnow JS et al. 1999 Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. Journal of Clinical Endocrinology and Metabolism 8, 228-232.
56. van Dessel HJ, Schoot BC, Schipper I et al. 1996 Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. Human Reproduction 11, 478-485.
57. van Santbrink EJ, Hop WC, van Dessel TJ et al. 1995 Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertility and Sterility 64, 37-43.
58. van Santbrink EJ, Fauser BC 1997 Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. Journal of Clinical Endocrinology and Metabolism 82, 3597-3602.
59. van Santbrink EJ, Eijkemans MJ, Macklon NS, Fauser BC 2002 FSH response-dose can be predicted in ovulation induction for normogonadotropic anovulatory infertility. European Journal of Endocrinology 147, 223-226.
60. van Weissenbruch MM, Schoemaker HC, Drexhage HA, Schoemaker J 1993 Pharmaco-dynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease. Human Reproduction 8, 813-821.
61. White DM, Polson DW, Kiddy D et al. 1996 Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. Journal of Clinical Endocrinology and Metabolism 81, 3821-3824.
62. Yarali H, Zeyneloglu HB 2004 Gonadotrophin treatment in patients with polycystic ovary syndrome. Reproductive BioMedicine Online 8, 528-537.
63. Yarali H, Yildiz BO, Demirol A et al. 2002 Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction 17, 289-294.
64. Yong EL, Barid DT, Hillier SG 1992 Mediation of gonadotropin-stimulated growth and differentiation of human granulosa cells by adenosine-3′,5′-monophosphate:one molecule, two messages. Clinical Endocrinology (Oxford) 37, 51-58.